-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Dapansutrile in Osteoarthritis Pain
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dapansutrile in Osteoarthritis Pain report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dapansutrile in Osteoarthritis Pain Drug Details: Dapansutrile (OLT-1177) is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Dapansutrile in Systolic Heart Failure
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dapansutrile in Systolic Heart Failure report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dapansutrile in Systolic Heart Failure Drug Details: Dapansutrile (OLT-1177) is under...
-
Product Insights
Systolic Heart Failure – Drugs In Development, 2023
Global Markets Direct’s, ‘Systolic Heart Failure - Drugs In Development, 2023’, provides an overview of the Systolic Heart Failure pipeline landscape. The report provides comprehensive information on the therapeutics under development for Systolic Heart Failure, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Gouty Arthritis (Gout) – Drugs In Development, 2023
Global Markets Direct’s, ‘Gouty Arthritis (Gout) - Drugs In Development, 2023’, provides an overview of the Gouty Arthritis (Gout) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Gouty Arthritis (Gout), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Musculoskeletal Inflammation – Drugs In Development, 2023
Global Markets Direct’s, ‘Musculoskeletal Inflammation - Drugs In Development, 2023’, provides an overview of the Musculoskeletal Inflammation pipeline landscape. The report provides comprehensive information on the therapeutics under development for Musculoskeletal Inflammation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Spinal Cord Injury – Drugs In Development, 2023
Global Markets Direct’s, ‘Spinal Cord Injury - Drugs In Development, 2023’, provides an overview of the Spinal Cord Injury pipeline landscape. The report provides comprehensive information on the therapeutics under development for Spinal Cord Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dapansutrile in Gouty Arthritis (Gout)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Dapansutrile in Gouty Arthritis (Gout) Drug Details: Dapansutrile (OLT-1177) is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Gene Therapy To Target Bcma And Cd19 For Blood Cancers And Systemic Lupus Erythematosus in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gene Therapy To Target Bcma And Cd19 For Blood Cancers And Systemic Lupus Erythematosus in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cemiplimab in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cemiplimab in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cemiplimab in Solid Tumor Drug Details: Cemiplimab (Libtayo) is an anti-neoplastic agent....